A team led by Northwestern Medicine investigators have discovered novel cellular mechanisms that lead to chemotherapy resistance in recurrent glioblastoma, according to findings published in Science Advances.
Men with high-risk prostate cancer who received immunotherapy treatment with enoblituzumab in the weeks leading up to surgery had favorable rates of disease remission and tumor downgrading after surgery, according to a recent study published in Nature Medicine.
Patients with endometrial cancer who received the immunotherapy drug pembrolizumab in addition to chemotherapy had longer progression-free survival compared to chemotherapy alone, according to a recent clinical trial published in the New England Journal of Medicine.
A Northwestern Medicine study used a novel ultrasound device to temporarily open the blood-brain barrier to deliver chemotherapy to treat glioblastoma.
Northwestern Medicine scientists have developed a biomarker signature test to predict which tumors will respond to immunotherapy.
A combination treatment approach using two chemotherapy drugs improved treatment response and progression-free survival in patients with advanced pancreatic neuroendocrine tumors, according to a recent clinical trial published in the Journal of Clinical Oncology.
Northwestern Medicine scientists have identified an enzyme which aids tumors in evading the immune system, findings that could provide future directions for tumor treatment, according to a study published in Nature Communications.
Northwestern University scientists have discovered it is possible to isolate a tumor’s attack cells non-invasively from blood, rather than from tumors.
Repeat radiation therapy combined with monoclonal antibody treatment extended progression-free survival in patients with recurrent glioblastoma, according to a recent clinical trial published in the Journal of Clinical Oncology.
Two therapeutic drugs benefited mice with non-small cell lung cancer, potentially paving the way for clinical trials in humans.